The global demand for Hereditary Angioedema Therapeutics Market is presumed to reach the market size of nearly USD 8.97 BN by 2030 from USD 4.6 BN in 2022 with a CAGR of 8.7% under the study period 2023 - 2030.
Hereditary Angioedema (HAE) therapeutics refers to the medical interventions and treatments designed to manage and alleviate the symptoms of Hereditary Angioedema, a rare genetic disorder. HAE presents with repeated instances of acute and significant swelling (referred to as angioedema) occurring in multiple regions of the body, including the face, limbs, gastrointestinal tract, and the airway.
The increasing awareness and improved diagnostic capabilities have led to a rise in diagnosed cases, fueling the demand for therapeutic interventions. Advancements in treatment options, including novel drugs and prophylactic approaches, play a pivotal role in enhancing outcomes for individuals with HAE. The designation of many HAE therapeutics as orphan drugs, along with associated regulatory incentives, encourages pharmaceutical investment in research and development. Patient advocacy groups and global research collaborations contribute to a supportive ecosystem, fostering innovation and understanding of HAE. The expansion of market players and government initiatives, coupled with rising healthcare expenditure, further propel the market by accelerating the development, approval, and accessibility of HAE therapeutics. Overall, the market dynamics are characterized by a concerted effort to address the challenges of this rare genetic disorder and improve the quality of life for affected individuals.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of hereditary angioedema therapeutics. The growth and trends of hereditary angioedema therapeutics industry provide a holistic approach to this study.
This section of the hereditary angioedema therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Treatment
By End-Use
By Route Of Administration
This section covers the regional outlook, which accentuates current and future demand for the Hereditary Angioedema Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Hereditary Angioedema Therapeutics market include BioCryst Pharmaceuticals Inc., Ionis Pharmaceuticals, CSL, Attune Pharmaceuticals, Adverum Biotechnologies Inc., KalVista Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Pharming. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . HEREDITARY ANGIOEDEMA THERAPEUTICS – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Treatment
3.7.2 Market Attractiveness Analysis By End-use
3.7.3 Market Attractiveness Analysis By Route of Administration
3.7.4 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET ANALYSIS BY TREATMENT
5.1 Overview by Treatment
5.2 Historical and Forecast Data
5.3 Analysis by Treatment
5.4 C1-esterase Inhibitor Historic and Forecast Sales by Regions
5.5 Bradykinin B2 Receptor Antagonist Historic and Forecast Sales by Regions
5.6 Kallikrein Inhibitor Historic and Forecast Sales by Regions
5.7 Others Historic and Forecast Sales by Regions
6 . GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET ANALYSIS BY END-USE
6.1 Overview by End-use
6.2 Historical and Forecast Data
6.3 Analysis by End-use
6.4 Prophylaxis Historic and Forecast Sales by Regions
6.5 On-demand Historic and ...